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Abstract
Introduction—Antimuscarinics should be used with caution in older adults with overactive 
bladder (OAB) due to anticholinergic adverse events (AEs). Systematic reviews and meta-analyses 
(SRMAs) have analyzed safety-related outcomes but have not specified risk in the elderly, the 
population at highest risk for AEs. The aim of this review is to explore and evaluate AEs and 
treatment discontinuations in adults 65 or older taking antimuscarinics for OAB.
Methods—Keywords were searched in MEDLINE, EMBASE, SCOPUS, and Cochrane Central 
Register for Controlled Trials. Randomized controlled trials (RCTs) along with sub-analyses and 
pooled analyses that compared antimuscarinics to placebo or another antimuscarinic were 
performed in February 2015. Studies assessing AEs or treatment discontinuations in a population 
of adults 65 or older were included. The Jadad Criteria and McHarm Tool were used to assess the 
quality of the trials.
Results—A total of 16 studies met the inclusion criteria. Eighty AEs and 27 reasons for 
treatment discontinuation were described in the included studies and further explored. 
Anticholinergic AEs were more common in antimuscarinics compared to placebo. Incidence of 
dizziness, dyspepsia, and urinary retention with fesoterodine, headache with darifenacin, and 
urinary tract infections with solifenacin were significantly higher compared to placebo. Treatment 
discontinuation due to AEs and dry mouth were higher in the antimuscarinics when compared to 
placebo in older adults.
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Conclusions—Treatment for overactive bladder using antimuscarinics in adults aged 65 or older 
resulted in significant increases in risk for several AEs compared to placebo including 
anticholinergic and non-anticholinergic AEs.
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1. Introduction
Overactive bladder (OAB) is a condition that can negatively impact quality of life in older 
adults. The prevalence of OAB in epidemiological studies increases with age (Gomelsky, 
2009; Milsom et al., 2000; Tubaro, 2004). Signs and symptoms of OAB such as urinary 
frequency, urgency, nocturia, and incontinence affect 25% of adults aged 60 or older 
(Scheife and Takeda, 2005; Wagg et al., 2010). There are several oral and non-oral treatment 
options for patients with OAB which include antimuscarinics (oxybutynin, tolterodine, 
trospium, darifenacin, solifenacin, fesoterodine) and a beta-3 agonist (mirabegron) (Kraus et 
al., 2010a; Macdiarmid, 2008). These medications are all viable options for the elderly. 
owever, providers should be cautioned in using these medications due to adverse drug events 
(AEs) including dry mouth, blurry vision, and constipation in antimuscarinics as well as 
hypertension in beta-3 agonists (Sternberg et al., 2011). These AEs may contribute to non-
adherence or discontinuation of the prescribed medication, which can lead to a return of 
OAB symptoms and a reduction in quality of life (Benner et al., 2010).
Several systematic reviews and meta-analyses have evaluated the use of medications in the 
treatment of OAB (Chapple et al., 2015; Chapple et al., 2008; Cui et al., 2014; Herbison et 
al., 2003; Huang et al., 2015; Kessler et al., 2011; Luo et al., 2012; Madhuvrata et al., 2012; 
Novara et al., 2008; Paquette et al., 2011; Reynolds et al., 2015; Roxburgh et al., 2007; Wu 
et al., 2014; Wyndaele et al., 2014). These reviews compared OAB medications to placebo 
and/or to other OAB medications, either directly or indirectly, using prospective randomized, 
non-randomized, and retrospective observational trials. Current systematic reviews have 
only described the individual studies with regards to the use of OAB medications in the 
elderly. No systematic review has used a meta-analytical technique to broadly explore safety 
outcomes in the elderly. The goal of this systematic review is to perform exploratory 
analyses of AEs and treatment discontinuations in oral and non-oral medications used to 
treat OAB in studies with patients aged 65 or older.
2. Materials and Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
statement was used for reporting this review. Institutional review board approval was not 
required for this review.
2.1 Literature Search
Studies involving patients aged 65 or older with OAB or urge urinary incontinence who 
received either an antimuscarinic (oxybutynin, tolterodine, trospium, solifenacin, 
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darifenacin, fesoterodine) or a beta-3 agonist (mirabegron) were included. Randomized-
controlled trials (RCTs) of one agent versus another agent or placebo (including studies with 
≥ two treatment arms), sub-analysis of a parent RCT, or pooled-results of two or more parent 
RCTs were included (Paquette et al., 2011). A parent study was defined as the original 
publication(s) in which a sub-analysis or pooled analysis was derived. Studies less than 4 
weeks in duration, those evaluating antimuscarinics in combination with alpha-blockers for 
lower urinary tract symptoms, populations in which neurogenic bladder or conditions other 
than OAB were studied, and any language other than English were excluded by title or 
abstract.
The following electronic databases were searched: MEDLINE (PubMed interface), 
EMBASE, SCOPUS, and Cochrane Central Register for Controlled Trials. The basic search 
strategy used derivations of the following strategy (aged AND [antimuscarinic agents OR 
beta-3 agonists OR oxybutynin OR tolterodine OR trospium OR darifenacin OR solifenacin 
OR fesoterodine OR mirabegron]). MeSH and EMTREE terms were used for MEDLINE 
and EMBASE, respectively, and the full search strategy is described in Appendix 1. 
Duplicates were removed and non-relevant studies were removed based on title and abstract 
(SMV); relevant full-text articles were identified. Two of the four authors (SMV, PMS, 
CDK, BFT) independently screened each full-text article using the pre-established criteria 
after a team training exercise. Studies were excluded for the following reasons: 1) did not 
report original data, 2) did not include an overactive bladder medication, 3) no comparator 
arm, 4) used a non-standard dose, route, and frequency (e.g., antimuscarinic combination 
therapy), 5) conducted in subjects without overactive bladder, 6) assessed only quality of life 
outcomes, 7) trial was less than 4 weeks in duration, 8) was not a randomized, controlled 
trial, 9) studies with outcomes that did not differentiate by age, 10) did not report safety 
outcomes, and 11) used a duplicate population. Any conflicts were resolved by consensus of 
the two authors.
2.2 Data Extraction
As this was an exploratory analysis, all AEs and treatment discontinuations reported in any 
included study were identified and collected by two authors (SMV, CDK) after a team 
training exercise. Any conflicts were resolved by consensus of the two authors. Once 
confirmed, a data extraction sheet was created. Study characteristics were extracted which 
included the last name of the first author, year published, journal, study type, study duration, 
overactive bladder medication and comparator, number of subjects, age cut points, OAB 
inclusion criteria, percent female, location of study, AEs, and treatment discontinuations as 
previously defined. Authors were contacted by email when all necessary data was not 
available in the manuscript; no additional data was incorporated from authors contacted by 
email. Two of four authors (SMV, PMS, CDK, BFT) independently extracted each study 
using the pre-established criteria after an additional training exercise. Any conflicts were 
resolved by consensus of the two authors. As AEs and treatment discontinuations were 
reported as dichotomous variables within the study, the timing of such events could not be 
assessed.
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The Jadad Criteria was used to appraise the risk of bias within the included studies (Jadad et 
al., 1996). For pooled analyses and sub-analyses studies, the parent studies were scored 
when available. The McMaster tool for assessing quality of harms assessment and reporting 
in study reports (McHarm Tool) was used to examine the consistency in reporting of AEs 
(Santaguida and Raina, 2008). Each study was extracted independently by two of four 
authors (SMV, PMS, CDK, BFT) using the pre-established criteria to create the Jadad 
Criteria Score and complete the McHarm Tool after an additional training exercise. A study 
with a Jadad Criteria score of 4 or greater was considered high quality. Any conflicts were 
resolved by consensus of the two authors.
2.4 Data Synthesis
The studies were synthesized using the above criteria and included the risk of bias and 
quality. These studies were assessed for heterogeneity using the I2 statistic; as a conservative 
estimate, random-effects models were used for all analyses. If the I2 statistic is <25%, then 
the authors reported no heterogeneity. If the I2 statistic is ≥ 25% then it will be denoted in 
the tables and the value reported out in the manuscript. Given that only four studies with 
four separate medications reported outcomes by differing doses, doses within each 
medication category were collapsed (Foote et al., 2005; Kraus et al., 2010b; Malone-Lee et 
al., 2001; Wagg et al., 2006). Medications were compared to placebo and any active 
comparator in separate analyses. Individual AEs and treatment discontinuations were 
described in rate ratios in an overall analysis and an analysis stratified by specific 
medication. For statistically significant AEs and treatment discontinuations, number needed 
to harm (NNH) were also calculated.
The lack of standardization in the reporting of AEs across studies was accounted for by 
combining similar AEs extracted from an individual study based on symptomatology to 
improve power in secondary analyses similar to the Common Terminology Criteria for 
Adverse Events v3.0 (CTCAE) (2009; Kessler et al., 2011).
3. Results
The search retrieved a total of 26,166 studies, of which 228 full-text studies were reviewed 
for inclusion in the systematic review (Figure 1). The most common reasons for exclusion 
were outcomes not being differentiated by age or a lack of a comparator arm. Seventeen 
studies (7 RCTs, 3 sub-analyses of RCTs, and 7 pooled analyses of RCTs) made the 
inclusion criteria in which AEs were reported in the 65 or older population. Safety endpoints 
could not be extracted from one pooled analysis of RCTs (Griebling et al., 2009) as AEs 
were reported graphically; therefore, 16 studies were used in these analyses (Chapple et al., 
2007a; Dubeau et al., 2014; DuBeau et al., 2012; Foote et al., 2005; Herschorn et al., 2011; 
Kraus et al., 2010b; Lackner et al., 2008; Malone-Lee et al., 2001; Minassian et al., 2007; 
Sand et al., 2011; Sand et al., 2004; Szonyi et al., 1995; Wagg et al., 2014; Wagg et al., 
2013; Wagg et al., 2006; Zinner et al., 2002).
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Study characteristics and Jadad Criteria Score (Table 1) and McHarm Tool (Appendix 2) 
were calculated from the included studies. The parent RCTs of the sub-analyses and pooled 
analyses, when available, were extracted to assess study duration, OAB inclusion criteria, 
location of study, Jadad Criteria Score (Table 1), and McHarm Tool (Appendix 2) (Appell et 
al., 2001; Cardozo et al., 2004; Chapple et al., 2007b; Chapple et al., 2004a; Chapple et al., 
2005; Chapple et al., 2004b; Dmochowski et al., 2008; Herschorn et al., 2013; Herschorn et 
al., 2010a; Herschorn et al., 2010b; Kaplan et al., 2011; Khullar et al., 2013; Nitti et al., 
2013; Nitti et al., 2007; Staskin et al., 2007; Van Kerrebroeck et al., 2001). The parent 
studies (3 studies) from one pooled analysis were unable to be assessed by the authors as the 
results were unpublished (Foote et al., 2005).
3.1 Study Quality
Five of the 7 RCTs studies and 10 of the 16 parent studies evaluated were of high quality 
(Table 1). The quality of AEs reporting in the RCTs and the parent studies reporting was 
assessed using the McHarm Tool (Appendix 2). Specifically, question 11 of the McHarm 
Tool asked “Did the authors specify if the harms reported encompass ALL the events 
collected, or a selected SAMPLE?” The authors answered either no or unclear to this 
question in all evaluated studies. Of the 23 studies that were evaluated (7 RCTs and 16 
parent studies) for reporting all events, 14 studies defined their parameters for reporting 
specific AEs (i.e., only if ≥ 2% in any group). It was unclear what proportion of AEs were 
reported in the remaining 9 studies.
3.2 Overactive Bladder Medications
The 16 included studies included analyses on oxybutynin immediate-release (IR) (Herschorn 
et al., 2011; Minassian et al., 2007; Szonyi et al., 1995), oxybutynin extended-release (ER) 
(Lackner et al., 2008; Minassian et al., 2007; Sand et al., 2011; Sand et al., 2004), 
tolterodine IR (Malone-Lee et al., 2001; Sand et al., 2004), tolterodine ER (DuBeau et al., 
2012; Wagg et al., 2014; Zinner et al., 2002), trospium ER (Sand et al., 2011), solifenacin 
(Herschorn et al., 2011; Wagg et al., 2006), darifenacin (Chapple et al., 2007a; Foote et al., 
2005), fesoterodine (Dubeau et al., 2014; DuBeau et al., 2012; Kraus et al., 2010b; Wagg et 
al., 2013), and mirabegron (Wagg et al., 2014). Thirteen studies were placebo controlled. 
Two studies compared solifenacin and oxybutynin ER to oxybutynin IR (Herschorn et al., 
2011; Minassian et al., 2007), one study compared oxybutynin ER to tolterodine IR (Sand et 
al., 2004), and one study compared fesoterodine to tolterodine ER (DuBeau et al., 2012). 
One study compared tolterodine ER, fesoterodine, mirabegron, and placebo (Wagg et al., 
2014). Using this study, the authors compared tolterodine ER to fesoterodine, fesoterodine 
and tolterodine ER to the same cohort of placebo. Additionally, this was the only study to 
assess mirabegron (compared to placebo and compared to tolterodine ER) (Wagg et al., 
2014). Due to the differing mechanism of action and AEs relative to antimuscarinics, 
mirabegron was not incorporated into the meta-analysis as the differences in AEs and 
treatment discontinuations were already reported.
In these analyses, 4,188 subjects (3952 subjects in placebo-controlled trials) aged 65 or older 
were randomized to antimuscarinics medications for 4 to 12 weeks and 3,026 were 
randomized to placebo. The number of subjects randomized to antimuscarinic treatment was 
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oxybutynin IR (n=88), oxybutynin ER (n=115), tolterodine IR (n=194), tolterodine ER 
(n=992), trospium ER (n=85), solifenacin (n=650), darifenacin (n=650), fesoterodine 
(n=1591).
From the overall 16 studies included for analyses, there were 80 distinct reports of AEs and 
27 distinct reports of treatment discontinuation. Many AEs reported severity of disease (i.e., 
mild to moderate urinary tract infection and severe urinary tract infection) without defining 
severity levels. As standard nomenclature was not routinely used, many AEs appeared to be 
very similar (i.e., vision disorder and blurry vision) which likely increased the number that 
were explored.
Outcomes for all AEs and treatment discontinuations for antimuscarinics versus placebo 
(Appendices 3,5) and antimuscarinic versus antimuscarinic (Appendices 4,6) are described 
regardless of being statistically significant. There were 14 statistically significant AEs (Table 
2), two statistically significant treatment discontinuations (Table 4), and one statistically 
significant combined AEs (Appendix 7) in the antimuscarinic versus placebo analyses. 
There were four statistically significant AEs (Table 3), one statistically significant treatment 
discontinuation (Table 5), and no statically significant combined AEs (Appendix 8) in the 
antimuscarinic versus antimuscarinic analyses.
3.3 Adverse Events
3.3.1 Antimuscarinics versus Placebo—Statistically significant rates for AEs and 
NNH for antimuscarinics compared to placebo are described in Table 2. The proportion of 
subjects with any AEs was 53.8% in those receiving an antimuscarinic compared to 41.7% 
in subjects receiving placebo. There was also an increase in treatment-related AEs which 
was more narrowly defined as adverse outcomes likely related to the study drug in studies 
assessing darifenacin and trospium ER.
Ten percent of subjects receiving an antimuscarinic experienced constipation compared to 
3.3% receiving placebo [I2=46.1%]. Darifenacin (18.0%), solifenacin (15.4%), fesoterodine 
(8.5%), and tolterodine (4.8%) had significantly higher rates of constipation among subjects 
receiving antimuscarinics compared to placebo. Within the same studies, 25% of subjects 
receiving an antimuscarinic experienced dry mouth compared to 5.3% of subjects receiving 
placebo [I2=73.9%]. There was a significantly higher rate of dry mouth with no 
heterogeneity among subjects in tolterodine ER (6.1%), darifenacin (23.8%), solifenacin 
(26.0%), and fesoterodine (29.4%) groups. A significantly higher proportions of subjects 
receiving an antimuscarinic experienced mild, mild-moderate, moderate, and severe dry 
mouth when compared to placebo.
There was no overall increase rate of dizziness in antimuscarinics compared to placebo; 
however, in three fesoterodine studies there was over a higher rate of dizziness (2.5%) 
compared to placebo (1%). Subjects receiving fesoterodine had significantly higher rate of 
dyspepsia (2.7%) compared to placebo (0.6%). In a subsequent analysis in which all 
gastrointestinal AEs were combined (abdominal pain, anorexia, dyspepsia, gastrointestinal 
AEs, gastroesophageal reflux disorder, heartburn), there was no significant difference in 
antimuscarinics (4.6%) compared to placebo (2.7%); however, in the three fesoterodine 
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studies that assessed any of these AEs, there was a significantly higher rate of 
gastrointestinal AEs (3.1%) compared to placebo (1.1%) (Appendix 7). There was no overall 
difference in headache between subjects receiving antimuscarinic compared to placebo; 
however, a higher rate was seen in the three studies in which subjects received tolterodine 
ER (1.7%) compared to placebo (0.7%). There was an overall higher rate of urinary 
retention in subjects receiving antimuscarinics (1.3%) compared to placebo (0.4%) and a 
higher rate in the four studies which assessed subjects receiving fesoterodine (1.7%) 
compared to placebo (0.2%). There was an increased rate of urinary tract infections in one 
study comparing solifenacin (6.0%) to placebo (3.1%); however, there was no difference in 
antimuscarinics (3.7%) overall versus placebo (2.8%).
3.3.2 Head-to-Head Trials—Statistically significant rate of AEs and NNH for an 
antimuscarinic compared to another antimuscarinic are described in Table 3. In these 
comparator studies, solifenacin exhibited a lower rate of AEs (70.4% versus 96.7%), 
treatment-related AEs (60.3% versus 86.7%), and dry mouth (37.0% versus 80.0%) 
compared to oxybutynin IR, respectively. Subjects receiving fesoterodine were more likely 
to experience AEs (54.8% versus 40.0%) and dry mouth (31.3% versus 14.7%) compared to 
tolterodine ER. There were no significant AEs when outcomes were combined based on 
symptomatology (Appendix 7).
3.4 Treatment Discontinuations
3.4.1 Antimuscarinic versus Placebo—Statistically significant rate of treatment 
discontinuation and NNH for antimuscarinics compared to placebo are described in Table 4. 
Of the 27 reasons for discontinuation, only two were statistically significant. Treatment 
discontinuation due to AEs was higher in the antimuscarinic group (7.1%) compared to 
placebo (5.0%); however, when stratified by medication, only fesoterodine (9.4%) compared 
to placebo (4.9%) was statistically significant for treatment discontinuation due to an AE. 
Overall, the discontinuation rate due to dry mouth was higher in antimuscarinics (1.5%) 
compared to placebo (0.4%) and in three comparisons of fesoterodine (2.0%) when 
compared to placebo (0.3%).
3.4.2 Head-to-Head Trials—Statistically significant rate of treatment discontinuation and 
NNH for an antimuscarinic compared to another antimuscarinic are described in Table 4. In 
the antimuscarinic comparators, only fesoterodine (8.6%) had a higher rate of 
discontinuation due to AEs compared to tolterodine ER (2.7%).
4. Discussion
The aim of these analyses was to assess the rate of AEs and treatment discontinuations with 
the use of antimuscarinics in the group of patients who are most likely to experience OAB. 
With a known lack of studies specific to older adults, sub-analyses and pooled analyses were 
included to increase the number of subjects similar to a previous systematic review and 
meta-analysis of antimuscarinics in older adults (Paquette et al., 2011). Data from the parent 
studies were used to assess for OAB inclusion criteria, location of study, and quality of 
studies. There were 18 comparisons from 16 studies which assessed several antimuscarinic 
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agents used for the treatment of OAB. A majority of studies were placebo-controlled while 
only 4 studies included direct comparisons to two antimuscarinic agents. In general, these 
studies were very similar in the included age (as only two studies used a minimum age 
inclusion criterion older than 65), OAB inclusion criteria (minor differences exists between 
duration of OAB symptoms, frequency, and urgency), proportion of females in trials (all 
were >50%), and location of the trial (all studies except for one was in a non-
institutionalized setting). Two-thirds of RCTs and parent studies were of high-quality using 
the Jadad criteria.
Current guidelines recommend the use of any antimuscarinic or beta-3 agonist as first-line 
drug treatment for OAB as efficacy among the two different classes are considered to be 
similar (Gormley et al., 2015; Thuroff et al., 2011). The approach to treating OAB in healthy 
older adults is similar to younger adults; however, frail older adults may have increased 
challenges as comorbidities, functional or cognitive deficits, and concomitant medications 
play a greater role in their management (Thuroff et al., 2011). Additionally, antimuscarinics 
in frail older adults may have a higher rate of AEs especially in the setting of polypharmacy 
(Geoffrion, 2012; Gormley et al., 2015).
In these analyses, AEs occurred at a higher rate in the antimuscarinic arms (53.8%) 
compared to placebo (41.7%) in this older adult population. Additionally, the 
discontinuation rate was also higher in the antimuscarinic group (7.1%) versus placebo 
(5.0%). This difference may be attributed to the higher rates of AEs. However, these studies 
are limited to up to 12 weeks of duration in patients who are willing to participate in a 
clinical trials and may not represent true rates of AEs and treatment discontinuation.
These findings show higher rates of anticholinergic AEs with antimuscarinics when 
compared to placebo in older adults. The overall rates of constipation and dry mouth in the 
antimuscarinic arms of these studies were 10% and 25%, respectively. Subjects in the 
darifenacin (18.0%) and solifenacin (15.4%) arms had the highest rates of constipation. The 
rates of dry mouth were also highest in the fesoterodine (29.4%), solifenacin (26.0%), and 
darifenacin (23.8%) arms. Compared to tolterodine ER (14.7%), there was a two-fold 
increase in dry mouth in subjects receiving fesoterodine (31.3%) suggesting a potential 
difference in rates of adverse outcomes between two antimuscarinics in older adults. This 
pooled analysis, which compared fesoterodine to tolterodine ER, suggested better efficacy in 
the fesoterodine arm with a statistically significant increase in dry mouth when compared to 
tolterodine ER (DuBeau et al., 2012). Fesoterodine is a pro-drug of tolterodine with doses of 
4mg and 8mg compared to tolterodine with doses of 2mg and 4mg. There was a 3-fold and 
4.8-fold increase rate of treatment discontinuation due to dry mouth observed in all 
antimuscarinics and fesoterodine, respectively, relative to placebo meaning dry mouth is 
bothersome enough to withdrawal from trials.
Older adults receiving fesoterodine (2.5%) were more likely to experience dizziness 
compared to placebo (1%). One alternative reason, beyond a true difference, for a higher rate 
of dizziness may be due to the increase sample size of subjects randomized to fesoterodine 
as 40% of subjects in the treatment arm were on fesoterodine in this analysis of older adults; 
therefore, it may be the only antimuscarinic with an adequate sample size needed to detect 
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this difference. Conversely, there was no overall difference in the rate of dizziness in 
antimuscarinics compared to placebo. Another reason is the impact of age and/or frailty on 
the outcome of dizziness. DuBeau and colleagues assessed fesoterodine (n=281) versus 
placebo (n=281) in a vulnerable older adult population, defined by a Vulnerable Elders 
Survey score of 3 or more; however, the rate of dizziness in this population was 1.1% in the 
treatment arm (Dubeau et al., 2014). Kraus and colleagues showed an age-related increase in 
dizziness in older adults compared to younger adults which may suggest and age-related 
increase in dizziness (Kraus et al., 2010b). Additionally, there may be differences in 
identifying and classifying dizziness as safety outcomes were a part of the secondary 
analysis. Dizziness was the only significant cognitive- or functional-related AE in the study 
population. A previous meta-systematic review investigated the rate of central nervous 
system AEs, including dizziness, in older adults (Paquette et al., 2011). Similar, low rates of 
dizziness were identified in the antimuscarinics evaluated except of oxybutynin (3.0%) and 
propiverine (3.2%) (fesoterodine was not yet approved); however, within this analysis 
central nervous system AEs were not measured and may be underreported. Although the rate 
is low, dizziness may contribute to falls and fall-related fractures which may negatively 
impact quality of life.
Older adults randomized to fesoterodine were at 4-fold rate of dyspepsia compared to 
placebo (2.7% versus 0.6%) which was not noted in any other antimuscarinic sub-analysis. 
In a previous systematic review, the proportion of subjects receiving antimuscarinics (4.7%) 
was higher than patients receiving placebo (2.1%) (Chapple et al., 2008). This may be due to 
the anticholinergic properties of antimuscarinics causing reduced lower esophageal pressures 
which can present as dyspepsia (Peters, 1989). The difference identified in fesoterodine and 
not the other antimuscarinics may be due to the sample size of the fesoterodine population 
and the use of fesoterodine in a frail population.
Headache was not significant in the overall analysis; however, there was a two-fold rate of 
headache with tolterodine ER (2.7%) compared to placebo (1.7%) in three studies which 
contained information on approximately 1000 subjects in both treatment and placebo arms. 
Authors of a previous systematic review were unable to determine the mechanistic 
difference between tolterodine and other antimuscarinics in regards to headache and 
differences may be due to chance (Chapple et al., 2008).
Urinary retention was also significantly higher in the overall antimuscarinic group (1.3%) 
compared to placebo (0.3%), especially in subjects receiving fesoterodine (1.7%) compared 
to placebo (0.2%). In general, males are likely to be at a higher risk of urinary retention, 
especially at advancing age, due to the risk of benign prostatic enlargement (Emberton and 
Anson, 1999). However, one oxybutynin ER study of women only in the long-term care 
setting, two fesoterodine studies, and one trospium study reported urinary retention 
separately by sex (Dubeau et al., 2014; Lackner et al., 2008; Wagg et al., 2013; Zinner et al., 
2002). The overall proportion of males (0.7%) and females (1.1%) with urinary retention 
was similar suggesting urinary retention is not an AE that affects only men; however, the 
risk of urinary retention in men is likely underestimated due to the exclusion of men with 
bladder outlet obstruction in these RCTs.
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There was nearly a two-fold increase in urinary tract infections in solifenacin (5.9%) 
compared to placebo (3.1%); however, there was no difference when evaluating all 
antimuscarinics versus placebo regarding urinary tract infections. The significant difference 
in solifenacin and placebo may due to an adequate sample size to detect a difference, 
random chance, or mechanistically, solifenacin is different from other antimuscarinics which 
may contribute to urinary tract infections.
4.1 Limitations
There are limitations to the study design. RCTs along with pooled and sub-analyses were the 
only study types included. These outcomes may not be generalizable to a clinical setting and 
may underrepresent the true rate of AEs and treatment discontinuations as there is the 
potential that subjects with higher risks of AEs and treatment discontinuations would be 
excluded for the study (Loke et al., 2007). Observational studies were not incorporated due 
to potential for inconsistent collection of AEs and treatment discontinuations across studies. 
Open-label studies with no comparator were not included for analysis as it may be difficult 
to discern between AEs and treatment discontinuations and the impact of aging. The 
duration of studies were 12 weeks or less; therefore, the authors cannot assess AEs and 
treatment discontinuations that may occur after continued use of antimuscarinics beyond 12 
weeks. This may not allow enough time for a subject to develop and be identified with 
cognitive-related AEs as these may not present until beyond three months (Han et al., 2008). 
Many studies did not describe a standardized way of identifying or reporting AEs or 
treatment discontinuations. While the majority reported any AEs that occurred in at least 5% 
of the subjects, there is a potential of not being able to identify all AEs across these studies, 
which may lead to an under identification of AEs and treatment discontinuations. Using the 
McHarm tool, the authors were able to be explicit on the differences in reporting AEs across 
studies. Similar terms, as previously described by Kessler, were used to combine potentially 
related AEs based on symptomatology (Kessler et al., 2011); however, no new significant 
AEs were detected. Efficacy was not analyzed in the systematic review and meta-analysis; 
therefore the authors cannot assess if the benefits of medications outweigh the risks of the 
various types of AEs. However, previous clinical guidelines suggest similar efficacy 
outcomes across antimuscarinics (Geoffrion, 2012; Gormley et al., 2015; Thuroff et al., 
2011). Heterogeneity was not further explored beyond stratification of antimuscarinics as 
this was an exploratory analysis to identify AEs and treatment discontinuations that can be 
tested in future observational studies. Mirabegron and non-oral antimuscarinics (i.e., 
oxybutynin patch, oxybutynin gel) were not incorporated into these analyses. Only one study 
has assessed mirabegron in older adults (DuBeau et al., 2012) and no studies have evaluated 
non-oral antimuscarinics in older adults. These medications may have a differing AE profile. 
The authors did not assess for publication bias using funnel plots; however, since AEs were 
secondary outcomes, with the exception of one study (Herschorn et al., 2011), the 
publication of these studies were less dependent on positive or negative results in the safety 
outcomes compared to primary efficacy outcomes.
4.2 Strengths
Despite these limitations, there were many strengths to the study. This is the second review 
to aggregate RCTs, pooled analyses of RCTs, and sub-analyses of RCTs AEs of 
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antimuscarinics (Paquette et al., 2011) and the first to perform an analysis of AEs beyond 
central-nervous system AEs with a large enough sample size to potentially detect differences 
in treatment groups that may not be able to be detected using individual studies. As RCTs 
were used in this analyses and not observational studies, the results are not impacted by 
channeling bias due to the random allocation of treatment and not on the preferential use of 
one medication over another based on clinical presentation and pre-existing comorbid 
conditions (Petri and Urquhart, 1991). The study also identified non-anticholinergic AEs 
which may not be routinely associated with antimuscarinics. Similar AEs were combined 
based on symptomatology to further explore AEs. Future studies to further explore less well-
documented antimuscarinic AEs using pharmacoepidemiological techniques should be 
performed. Properly attributing AEs to antimuscarinics may help identify alternative 
therapies and avoid prescribing cascades (Rochon and Gurwitz, 1997).
5. Conclusion
Treatment for overactive bladder using antimuscarinics in adults aged 65 or older resulted in 
significant increase risk of several AEs compared to placebo including both anticholinergic 
(e.g., dry mouth, constipation) and non-anticholinergic (e.g., dyspepsia, dizziness, 
headaches) AEs. Pharmacoepidemiology studies are needed to confirm AEs described in 
these analyses in a clinical setting. Differences in AEs, dry mouth, and discontinuation rates 
due to AEs were identified in head-to-head trials.
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Appendix 1: Complete Search Strategy
PubMed
(“aged” OR “Aged”[Mesh] OR “elderly” OR “aged, 80 and over”[Mesh] OR “aged, 80 and 
over” OR “oldest old” OR “nonagenarian*” OR “octogenarian*” OR “centenarian*” OR 
“frail elderly”[Mesh] OR “frail elder*” OR “functionally-impaired elderly” OR “frail older 
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adult*” OR “retire*” OR “septuagenarian*” OR “sexagenarian*” OR “geriatric*” OR 
“senior citizen”) AND (“Muscarinic Antagonists”[Mesh] OR “Antagonists, Muscarinic” OR 
“Antimuscarinics” or “Antimuscarinic Agents” OR “Agents, Antimuscarinic” OR 
“Cholinergic Muscarinic Antagonists” OR “Antagonists, Cholinergic Muscarinic” OR 
“Muscarinic Antagonists, Cholinergic” OR “Antimuscarinic agent” OR “antimuscarinic 
drug” OR “muscarinic blocker” OR “muscarinic blocking agent” OR “muscarinic receptor 
antagonist” OR “muscarinic receptor blocker” OR “oxybutynin” [Supplementary Concept] 
OR “oxybutynin” OR “K9P6MC7092” OR “Zatur” OR “Contimin” OR “Cystonorm” OR 
“Ditropan” OR “Dridase” OR “Cystrin” OR “Dresplan” OR “Driptane” OR “gelnique” OR 
“Gen-Oxybutynin” OR “Novo-Oxybutynin” OR “Nu-Oxybutyn” OR “Oxyb AbZ” OR 
“Oxybutin Holsten” OR “Oxybuton” OR “Oxybutynin AL” OR “Oxybutynin AZU” OR 
“Oxybutynin Heumann” OR “Oxybutynin Hexal” OR “oxybutynin hydrochloride” OR 
“oxybutynin chloride” OR “Oxybutynin Stada” OR “oxybutynin von ct” OR “Oxybutynin-
Puren” OR “Oxybutynin-ratiopharm” OR “Oxymedin” OR “Oxytrol” OR “PMS-
Oxybutynin” OR “Pollakisu” OR “Renamel” OR “Ryol” OR “Spasmex” OR “Oxybutynin” 
OR “Spasyt” OR “Tavor” OR “Oxybugamma” OR “Apo-Oxybutynin” OR “tolterodine” 
[Supplementary Concept] OR “WHE7A56U7K” OR “PHA-686464B” OR “Urotrol” OR 
“Detrol” OR “Unidet” OR “Detrusitol” OR “tolterodine tartrate” OR “trospium chloride” 
[Supplementary Concept] OR “trospium chloride” OR “1E6682427E” OR “azoniaspiro 
compound XVII” OR OR “Spasmex” OR “Uraton” OR “Spasmolyt” OR “Spasmo-Urgenin 
TC” OR “Spasmo-lyt” OR “Spasmo-Rhoival TC” OR “Trospi” OR “Ceris” OR “Uraplex” 
OR “Spasmo-Urgenin” OR “Sanctura” OR “solifenacin” [Supplementary Concept] OR 
“solifenacin” OR “A8910SQJ1U” OR “YM905” OR “YM 905” OR “solifenacin succinate” 
OR “vesicare” OR “darifenacin” [Supplementary Concept] OR “darifenacin” OR 
“darifenacin” OR “darifenacine” OR “darifenacin hydrochloride” OR “Enablex” OR 
“UK-88525” OR “darifenacin hydrobromide” OR “Emselex” OR “APG9819VLM” OR 
“fesoterodine” [Supplementary Concept] OR “fesoterodine” OR “621G617227” OR 
“toviaz” OR “fesoterodine fumarate” OR Mirabegron” OR “mirabegron” [Supplementary 
Concept] OR “MVR3JL3B2V” OR “Betanis” OR “YM 178” OR “YM-178” OR 
“Adrenergic beta-3 Receptor Agonists”)
EMBASE
(‘aged’/exp OR ‘aged’ OR ‘frail elderly’/exp OR ‘very elderly’/exp OR ‘very elderly’ OR 
‘geriatrics’/exp OR ‘geriatrics’ OR ‘geriatric patient’/exp OR ‘geriatric patient’ OR ‘elderly’ 
OR ‘aged, 80 and over’ OR ‘oldest old’ OR ‘nonagenarian’ OR ‘nonagenarians’ OR 
‘octogenarian’ OR ‘octogenarians’ OR ‘centenarian’ OR ‘centenarians’ OR ‘frail elder’ OR 
‘frail elders’ OR ‘frail elderly’ OR ‘functionally-impaired elderly’ OR ‘frail older adult’ OR 
‘frail older adults’ OR ‘retiree’ OR ‘septuagenarian’ OR ‘septuagenarians’ OR 
‘sexagenarian’ OR ‘sexagenarians’ OR ‘geriatric’ OR ‘senior citizen’) AND (‘muscarinic 
receptor blocking agent’/exp OR ‘Antagonists, Muscarinic’ OR ‘Antimuscarinics’ or 
‘Antimuscarinic Agents’ OR ‘Agents, Antimuscarinic’ OR ‘Cholinergic Muscarinic 
Antagonists’ OR ‘Antagonists, Cholinergic Muscarinic’ OR ‘Muscarinic Antagonists, 
Cholinergic’ OR ‘Antimuscarinic agent’ OR ‘antimuscarinic drug’ OR ‘muscarinic 
antagonist’ OR ‘muscarinic antagonists’ OR ‘muscarinic blocker’ OR ‘muscarinic blocking 
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agent’ OR ‘muscarinic receptor antagonist’ OR ‘muscarinic receptor blocker’ OR 
‘muscarinolytic agent’ OR ‘oxybutynin’/exp OR ‘anturol’ OR ‘cystonorm’ OR ‘cystrin’ OR 
‘delifon’ OR ‘ditropan’ OR ‘ditropan xl’ OR ‘diutropin’ OR ‘dridase’ OR ‘driptane’ OR 
‘esoxybutynin’ OR ‘esoxybutynin chloride’ OR ‘frenurin’ OR ‘gelnique’ OR ‘iliaden’ OR 
‘kentera’ OR ‘kl 007’ OR ‘kl007’ OR ‘lenditro’ OR ‘lyrinel xl’ OR ‘mj 4309 1’ OR ‘mj 
43091’ OR ‘mj43091’ OR ‘mutum cr’ OR ‘nefryl’ OR ‘novitropan’ OR ‘oxibutinin’ OR 
‘oxibutynin’ OR ‘oxyban’ OR ‘oxybutinin’ OR ‘oxybutinin chloride’ OR ‘oxybutyin’ OR 
‘oxybutyin chloride’ OR ‘oxybutynin chlorhydrate’ OR ‘oxybutynin chloride’ OR 
‘oxybutynin hydrochloride’ OR ‘oxytrol’ OR ‘oxytrol for women’ OR ‘oyrobin’ OR 
‘pollakis’ OR ‘reteven’ OR ‘tropan’ OR ‘uricont’ OR ‘uroflax’ OR ‘urotrol’ OR ‘zatur ge’ 
OR ‘Zatur’ OR ‘Contimin’ OR ‘Cystonorm’ OR ‘Dresplan’ OR ‘Driptane’ OR ‘gelnique’ 
OR ‘Gen-Oxybutynin’ OR ‘Novo-Oxybutynin’ OR ‘Nu-Oxybutyn’ OR ‘Oxyb AbZ’ OR 
‘Oxybutin Holsten’ OR ‘Oxybuton’ OR ‘Oxybutynin AL’ OR ‘Oxybutynin AZU’ OR 
‘Oxybutynin Heumann’ OR ‘Oxybutynin Hexal’ OR ‘oxybutynin hydrochloride’ OR 
‘Oxybutynin Stada’ OR ‘oxybutynin von ct’ OR ‘Oxybutynin-Puren’ OR ‘Oxybutynin-
ratiopharm’ OR ‘Oxymedin’ OR ‘Pollakisu’ OR ‘Renamel’ OR ‘Ryol’ OR ‘Spasmex’ OR 
‘Spasyt’ OR ‘Tavor’ OR ‘Oxybugamma’ OR ‘Apo-Oxybutynin’ OR ‘tolterodine’/exp OR 
‘detrol’ OR ‘detrol la’ OR ‘detrusitol’ OR ‘pnu 200583’ OR ‘pnu200583’ OR ‘tolterodine 
tartrate’ OR ‘WHE7A56U7K’ OR ‘PHA-686464B’ OR ‘Urotrol’ OR ‘Unidet’ OR 
‘trospium chloride’/exp OR ‘regurin’ OR ‘sanctura’ OR ‘sanctura xr’ OR ‘spasmex’ OR 
‘spasmo urgenin’ OR ‘spasmo-lyt’ OR ‘spasmolyt’ OR ‘spasmourgenin’ OR ‘trospium 
chloride’ OR ‘1E6682427E’ OR ‘azoniaspiro compound XVII’ OR ‘Spasmex’ OR ‘Uraton’ 
OR ‘Spasmo-Urgenin TC’ OR ‘Spasmo-Rhoival TC’ OR ‘Trospi’ OR ‘Ceris’ OR ‘Uraplex’ 
OR ‘Spasmo-Urgenin’ OR ‘Sanctura’ OR ‘solifenacin’/exp OR ‘solifenacin succinate’ OR 
‘vesicare’ OR ‘vesikur’ OR ‘ym 53705’ OR ‘ym 905’ OR ‘ym53705’ OR ‘ym905’ OR 
‘A8910SQJ1U’ OR ‘darifenacin’/exp OR ‘darifenacin hydrobromide’ OR ‘emselex’ OR 
‘enablex’ OR ‘uk 88525’ OR ‘uk 88525 04’ OR ‘uk 88525-04’ OR ‘uk88525’ OR ‘uk88525 
04’ OR ‘uk88525-04’ OR ‘darifenacine’ OR ‘darifenacin hydrochloride’ OR ‘UK-88525’ 
OR ‘APG9819VLM’ OR ‘fesoterodine’/exp OR ‘fesoterodine fumarate’ OR ‘fesoterodine 
hydrogen fumarate’ OR ‘spm 907’ OR ‘spm907’ OR ‘toviaz’ OR ‘621G617227’ OR 
‘mirabegron’/exp OR ‘betanis’ OR ‘betmiga’ OR ‘myrbetriq’ OR ‘sc 211912’ OR 
‘sc211912’ OR ‘ym 178’ OR ‘ym178’ OR ‘MVR3JL3B2V’ OR ‘YM-178’ OR ‘Adrenergic 
beta-3 Receptor Agonists’)
SCOPUS
(TITLE-ABS-KEY(“aged”) OR TITLE-ABS-KEY(“elderly”) OR TITLE-ABS-KEY(“aged, 
80 and over”) OR TITLE-ABS-KEY(“oldest old”) OR TITLE-ABS-KEY(“nonagenarian*”) 
OR TITLE-ABS-KEY(“octogenarian*”) OR TITLE-ABS-KEY(“centenarian*”) OR 
TITLE-ABS-KEY(“frail elder*”) OR TITLE-ABS-KEY(“functionally-impaired elderly”) 
OR TITLE-ABS-KEY(“frail older adult*”) OR TITLE-ABS-KEY(“retire*”) OR TITLE-
ABS-KEY(“septuagenarian*”) OR TITLE-ABS-KEY(“sexagenarian*”) OR TITLE-ABS-
KEY(“geriatric*”) OR TITLE-ABS-KEY(“senior citizen”) OR TITLE-ABS-KEY(“very 
elderly”) OR TITLE-ABS-KEY(“geriatric patient”)) AND (TITLE-ABS-KEY(“Muscarinic 
Antagonists”) OR TITLE-ABS-KEY(“Antagonists, Muscarinic”) OR TITLE-ABS-
Vouri et al. Page 17





















KEY(“Antimuscarinics”) OR TITLE-ABS-KEY (“Antimuscarinic Agents”) OR TITLE-
ABS-KEY(“Agents, Antimuscarinic”) OR TITLE-ABS-KEY(“Cholinergic Muscarinic 
Antagonists”) OR TITLE-ABS-KEY(“Antagonists, Cholinergic Muscarinic”) OR TITLE-
ABS-KEY(“Muscarinic Antagonists, Cholinergic”) OR TITLE-ABS-KEY(“Antimuscarinic 
agent”) OR TITLE-ABS-KEY(“antimuscarinic drug”) OR TITLE-ABS-KEY(“muscarinic 
blocker”) OR TITLE-ABS-KEY(“muscarinic blocking agent”) OR TITLE-ABS-
KEY(“muscarinic receptor antagonist”) OR TITLE-ABS-KEY(“muscarinic receptor 
blocker”) OR TITLE-ABS-KEY(“oxybutynin”) OR TITLE-ABS-KEY(“K9P6MC7092”) 
OR TITLE-ABS-KEY(“Zatur”) OR TITLE-ABS-KEY(“Contimin”) OR TITLE-ABS-
KEY(“Cystonorm”) OR TITLE-ABS-KEY(“Ditropan”) OR TITLE-ABS-KEY(“Dridase”) 
OR TITLE-ABS-KEY(“Cystrin”) OR TITLE-ABS-KEY(“Dresplan”) OR TITLE-ABS-
KEY(“Driptane”) OR TITLE-ABS-KEY(“gelnique”) OR TITLE-ABS-KEY(“Gen-
Oxybutynin”) OR TITLE-ABS-KEY(“Novo-Oxybutynin”) OR TITLE-ABS-KEY(“Nu-
Oxybutyn”) OR TITLE-ABS-KEY(“Oxyb AbZ”) OR TITLE-ABS-KEY(“Oxybutin 
Holsten”) OR TITLE-ABS-KEY(“Oxybuton”) OR TITLE-ABS-KEY(“Oxybutynin AL”) 
OR TITLE-ABS-KEY(“Oxybutynin AZU”) OR TITLE-ABS-KEY(“Oxybutynin 
Heumann”) OR TITLE-ABS-KEY(“Oxybutynin Hexal”) OR TITLE-ABS-
KEY(“oxybutynin hydrochloride”) OR TITLE-ABS-KEY(“oxybutynin chloride”) OR 
TITLE-ABS-KEY(“Oxybutynin Stada”) OR TITLE-ABS-KEY(“oxybutynin von ct”) OR 
TITLE-ABS-KEY(“Oxybutynin-Puren”) OR TITLE-ABS-KEY(“Oxybutynin-ratiopharm”) 
OR TITLE-ABS-KEY(“Oxymedin”) OR TITLE-ABS-KEY(“Oxytrol”) OR TITLE-ABS-
KEY(“PMS-Oxybutynin”) OR TITLE-ABS-KEY(“Pollakisu”) OR TITLE-ABS-
KEY(“Renamel”) OR TITLE-ABS-KEY(“Ryol”) OR TITLE-ABS-KEY(“Spasmex”) OR 
TITLE-ABS-KEY(“Oxybutynin”) OR TITLE-ABS-KEY(“Spasyt”) OR TITLE-ABS-
KEY(“Tavor”) OR TITLE-ABS-KEY(“Oxybugamma”) OR TITLE-ABS-KEY(“Apo-
Oxybutynin”) OR TITLE-ABS-KEY(“tolterodine”) OR TITLE-ABS-
KEY(“WHE7A56U7K”) OR TITLE-ABS-KEY(“PHA-686464B”) OR TITLE-ABS-
KEY(“Urotrol”) OR TITLE-ABS-KEY(“Detrol”) OR TITLE-ABS-KEY(“Unidet”) OR 
TITLE-ABS-KEY(“Detrusitol”) OR TITLE-ABS-KEY(“tolterodine tartrate”) OR TITLE-
ABS-KEY(“trospium chloride”) OR TITLE-ABS-KEY(“trospium chloride”) OR TITLE-
ABS-KEY(“1E6682427E”) OR TITLE-ABS-KEY(“azoniaspiro compound XVII”) OR 
TITLE-ABS-KEY(“Spasmex”) OR TITLE-ABS-KEY(“Uraton”) OR TITLE-ABS-
KEY(“Spasmolyt”) OR TITLE-ABS-KEY(“Spasmo-Urgenin TC”) OR TITLE-ABS-
KEY(“Spasmo-lyt”) OR TITLE-ABS-KEY(“Spasmo-Rhoival TC”) OR TITLE-ABS-
KEY(“Trospi”) OR TITLE-ABS-KEY(“Ceris”) OR TITLE-ABS-KEY(“Uraplex”) OR 
TITLE-ABS-KEY(“Spasmo-Urgenin”) OR TITLE-ABS-KEY(“Sanctura”) OR TITLE-
ABS-KEY(“solifenacin”) OR TITLE-ABS-KEY(“solifenacin”) OR TITLE-ABS-
KEY(“A8910SQJ1U”) OR TITLE-ABS-KEY(“YM905”) OR TITLE-ABS-KEY(“YM 
905”) OR TITLE-ABS-KEY(“solifenacin succinate”) OR TITLE-ABS-KEY(“vesicare”) 
OR TITLE-ABS-KEY(“darifenacin”) OR TITLE-ABS-KEY(“darifenacin”) OR TITLE-
ABS-KEY(“darifenacin”) OR TITLE-ABS-KEY(“darifenacine”) OR TITLE-ABS-
KEY(“darifenacin hydrochloride”) OR TITLE-ABS-KEY(“Enablex”) OR TITLE-ABS-
KEY(“UK-88525”) OR TITLE-ABS-KEY(“darifenacin hydrobromide”) OR TITLE-ABS-
KEY(“Emselex”) OR TITLE-ABS-KEY(“APG9819VLM”) OR TITLE-ABS-
KEY(“fesoterodine”) OR TITLE-ABS-KEY(“fesoterodine”) OR TITLE-ABS-
Vouri et al. Page 18





















KEY(“621G617227”) OR TITLE-ABS-KEY(“toviaz”) OR TITLE-ABS-KEY(“fesoterodine 
fumarate”) OR TITLE-ABS-KEY(“Adrenergic beta-3 Receptor Agonists”) OR TITLE-
ABS-KEY(“Mirabegron”) OR TITLE-ABS-KEY(“Mirabegron”) OR TITLE-ABS-
KEY(“MVR3JL3B2V”) OR TITLE-ABS-KEY(“Betanis”) OR TITLE-ABS-KEY(“YM 
178”) OR TITLE-ABS-KEY(“YM-178”))
COCHRAN RCTs
(“aged” OR “Aged” OR “elderly” OR “aged, 80 and over” OR “aged, 80 and over” OR 
“oldest old” OR “nonagenarian*” OR “octogenarian*” OR “centenarian*” OR “frail 
elderly”[Mesh] OR “frail elder*” OR “functionally-impaired elderly” OR “frail older 
adult*” OR “retire*” OR “septuagenarian*” OR “sexagenarian*” OR “geriatric*” OR 
“senior citizen”) AND (“Muscarinic Antagonists” OR “Antagonists, Muscarinic” OR 
“Antimuscarinics” or “Antimuscarinic Agents” OR “Agents, Antimuscarinic” OR 
“Cholinergic Muscarinic Antagonists” OR “Antagonists, Cholinergic Muscarinic” OR 
“Muscarinic Antagonists, Cholinergic” OR “Antimuscarinic agent” OR “antimuscarinic 
drug” OR “muscarinic blocker” OR “muscarinic blocking agent” OR “muscarinic receptor 
antagonist” OR “muscarinic receptor blocker” OR “oxybutynin” OR “oxybutynin” OR 
“K9P6MC7092” OR “Zatur” OR “Contimin” OR “Cystonorm” OR “Ditropan” OR 
“Dridase” OR “Cystrin” OR “Dresplan” OR “Driptane” OR “gelnique” OR “Gen-
Oxybutynin” OR “Novo-Oxybutynin” OR “Nu-Oxybutyn” OR “Oxyb AbZ” OR “Oxybutin 
Holsten” OR “Oxybuton” OR “Oxybutynin AL” OR “Oxybutynin AZU” OR “Oxybutynin 
Heumann” OR “Oxybutynin Hexal” OR “oxybutynin hydrochloride” OR “oxybutynin 
chloride” OR “Oxybutynin Stada” OR “oxybutynin von ct” OR “Oxybutynin-Puren” OR 
“Oxybutynin-ratiopharm” OR “Oxymedin” OR “Oxytrol” OR “PMS-Oxybutynin” OR 
“Pollakisu” OR “Renamel” OR “Ryol” OR “Spasmex” OR “Oxybutynin” OR “Spasyt” OR 
“Tavor” OR “Oxybugamma” OR “Apo-Oxybutynin” OR “tolterodine” OR 
“WHE7A56U7K” OR “PHA-686464B” OR “Urotrol” OR “Detrol” OR “Unidet” OR 
“Detrusitol” OR “tolterodine tartrate” OR “trospium chloride” OR “trospium chloride” OR 
“1E6682427E” OR “azoniaspiro compound XVII” OR OR “Spasmex” OR “Uraton” OR 
“Spasmolyt” OR “Spasmo-Urgenin TC” OR “Spasmo-lyt” OR “Spasmo-Rhoival TC” OR 
“Trospi” OR “Ceris” OR “Uraplex” OR “Spasmo-Urgenin” OR “Sanctura” OR 
“solifenacin” OR “solifenacin” OR “A8910SQJ1U” OR “YM905” OR “YM 905” OR 
“solifenacin succinate” OR “vesicare” OR “darifenacin” OR “darifenacin” OR “darifenacin” 
OR “darifenacine” OR “darifenacin hydrochloride” OR “Enablex” OR “UK-88525” OR 
“darifenacin hydrobromide” OR “Emselex” OR “APG9819VLM” OR “fesoterodine” OR 
“fesoterodine” OR “621G617227” OR “toviaz” OR “fesoterodine fumarate” OR 
“Mirabegron” OR “mirabegron” OR “MVR3JL3B2V” OR “Betanis” OR “YM 178” OR 
“YM-178” OR “Adrenergic beta-3 Receptor Agonists”)
Appendix 2. McMaster Tool for Assessing Quality of Harms Assessments 
and Reporting in Study Reports (McHarm) of Included and Parent Studies
Vouri et al. Page 19
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Appendix 3: Adverse Events – Antimuscarinic versus Placebo
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Appendix 4. Adverse Events – Antimuscarinic versus Tolterodine IR/ER or 
Oxybutynin IR
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Appendix 5: Reasons for Treatment Discontinuation – Antimuscarinic 
versus Placebo
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Appendix 6. Reasons for Treatment Discontinuation – Antimuscarinic 
versus Tolterodine IR/ER or Oxybutynin IR
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Appendix 7. Combined Adverse Events – Antimuscarinic versus Placebo
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Appendix 8: Combined Adverse Events – Antimuscarinic versus 
Tolterodine IR/ER or Oxybutynin IR
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Appendix 9: Forest Plots for All Analysis
Appendix 9.001: Adnominal Pain (Antimuscarinics versus Placebo)
Appendix 9.002: Abnormal Accommodation (Antimuscarinics versus Placebo)
Appendix 9.003: Adverse Events (Antimuscarinics versus Placebo)
Appendix 9.004: Adverse Events, Severe (Antimuscarinics versus Placebo)
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Appendix 9.005: Anorexia (Antimuscarinics versus Placebo)
Appendix 9.006: Arthralgia (Antimuscarinics versus Placebo)
Appendix 9.007: Atrial Fibrillation (Antimuscarinics versus Placebo)
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Appendix 9.008: Back Pain (Antimuscarinics versus Placebo)
Appendix 9.009: Balance Disorder (Antimuscarinics versus Placebo)
Appendix 9.010: Blurred Vision (Antimuscarinics versus Placebo)
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Appendix 9.011: Bronchitis (Antimuscarinics versus Placebo)
Appendix 9.012: Cardiovascular Disease Adverse Event (Antimuscarinics versus Placebo)
Appendix 9.013: Cognitive Adverse Events (Antimuscarinics versus Placebo)
Zero Outcomes
Appendix 9.014: Confusional State (Antimuscarinics versus Placebo)
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Appendix 9.015: Constipation (Antimuscarinics versus Placebo)
Appendix 9.016: Constipation, Mild (Antimuscarinics versus Placebo)
Appendix 9.017: Constipation, Mild-Moderate (Antimuscarinics versus Placebo)
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Appendix 9.018: Constipation, Moderate (Antimuscarinics versus Placebo)
Appendix 9.019: Constipation, Severe (Antimuscarinics versus Placebo)
Appendix 9.020: Contusion (Antimuscarinics versus Placebo)
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Appendix 9.021: Cough (Antimuscarinics versus Placebo)
Appendix 9.022: Diarrhea (Antimuscarinics versus Placebo)
Appendix 9.023: Dizziness (Antimuscarinics versus Placebo)
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Appendix 9.024: Dry Eyes (Antimuscarinics versus Placebo)
Appendix 9.025: Dry Mouth (Antimuscarinics versus Placebo)
Appendix 9.026: Dry Mouth, Mild (Antimuscarinics versus Placebo)
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Appendix 9.027: Dry Mouth, Mild-Moderate (Antimuscarinics versus Placebo)
Appendix 9.028: Dry Mouth, Moderate (Antimuscarinics versus Placebo)
Appendix 9.029: Dry Mouth, Severe (Antimuscarinics versus Placebo)
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Appendix 9.030: Dry Skin (Antimuscarinics versus Placebo)
Appendix 9.031: Dry Throat (Antimuscarinics versus Placebo)
Appendix 9.032: Dyspepsia (Antimuscarinics versus Placebo)
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Appendix 9.033: Dysuria (Antimuscarinics versus Placebo)
Appendix 9.034: Edema (Antimuscarinics versus Placebo)
Appendix 9.035: Epistaxis (Antimuscarinics versus Placebo)
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Appendix 9.036: Facial Drop (Antimuscarinics versus Placebo)
Appendix 9.037: Fall (Antimuscarinics versus Placebo)
Appendix 9.038: Fatigue (Antimuscarinics versus Placebo)
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Appendix 9.039: Flatulence (Antimuscarinics versus Placebo)
Appendix 9.040: Gastroesophageal Reflux Disorder (Antimuscarinics versus Placebo)
Appendix 9.041: Headache (Antimuscarinics versus Placebo)
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Appendix 9.042: Heartburn (Antimuscarinics versus Placebo)
Appendix 9.043: Hypertension (Antimuscarinics versus Placebo)
Appendix 9.044: Increased Post-Void Residual Volume (Antimuscarinics versus Placebo)
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Appendix 9.045: Influenza (Antimuscarinics versus Placebo)
Appendix 9.046: Insomnia (Antimuscarinics versus Placebo)
Appendix 9.047: Memory Impairment (Antimuscarinics versus Placebo)
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Appendix 9.048: Muscle Spasms (Antimuscarinics versus Placebo)
Appendix 9.049: Nasal Dryness (Antimuscarinics versus Placebo)
Appendix 9.050: Nasopharyngitis (Antimuscarinics versus Placebo)
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Appendix 9.051: Nausea (Antimuscarinics versus Placebo)
Appendix 9.052: Nervous System Adverse Event (Antimuscarinics versus Placebo)
Appendix 9.053: Nervousness (Antimuscarinics versus Placebo)
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Appendix 9.054: Pain in Extremity (Antimuscarinics versus Placebo)
Appendix 9.055: Palpitations (Antimuscarinics versus Placebo)
Appendix 9.056: Paranoia (Antimuscarinics versus Placebo)
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Appendix 9.057: Pruritus (Antimuscarinics versus Placebo)
Appendix 9.058: Rash (Antimuscarinics versus Placebo)
Appendix 9.059: Renal Colic (Antimuscarinics versus Placebo)
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Appendix 9.060: Serious Adverse Events (Antimuscarinics versus Placebo)
Appendix 9.061: Sinusitis (Antimuscarinics versus Placebo)
Appendix 9.062: Somnolence (Antimuscarinics versus Placebo)
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Appendix 9.063: Toothache (Antimuscarinics versus Placebo)
Appendix 9.064: Treatment-related Adverse Events (Antimuscarinics versus Placebo)
Appendix 9.065: Treatment-emergent Glaucoma (Antimuscarinics versus Placebo)
Zero Outcomes
Appendix 9.066: Upper Respiratory Tract Infection (Antimuscarinics versus Placebo)
Vouri et al. Page 57





















Appendix 9.067: Urinary Retention (Antimuscarinics versus Placebo)
Appendix 9.068: Urinary Tract Infection (Antimuscarinics versus Placebo)
Appendix 9.069: Urinary Tract Infection, Mild-Moderate (Antimuscarinics versus Placebo)
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Appendix 9.070: Urinary Tract Infection, Severe (Antimuscarinics versus Placebo)
Zero Outcomes
Appendix 9.071: Urticaria (Antimuscarinics versus Placebo)
Appendix 9.072: Vertigo (Antimuscarinics versus Placebo)
Zero Outcomes
Appendix 9.073: Visual Disturbance (Antimuscarinics versus Placebo)
Zero Outcomes
Appendix 9.074: Vomiting (Antimuscarinics versus Placebo)
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Appendix 9.075: Abdominal Pain (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.076: Adverse Events (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.077: Adverse Events, Mild (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.078: Adverse Events, Moderate (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.079: Adverse Events, Severe (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.080: Back Pain (Other Antimuscarinics versus Oxybutynin IR)
Zero Outcomes
Appendix 9.081: Confusional State (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.082: Constipation (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.083: Cough (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.084: Dizziness (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.085: Dry Eyes (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.086: Dry Mouth (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.087: Dry Mouth, Mild (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.088: Dry Mouth, Moderate (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.089: Dry Mouth, Severe (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.090: Dry Skin (Other Antimuscarinics versus Oxybutynin IR)
Zero Outcomes
Appendix 9.091: Dry Throat (Other Antimuscarinics versus Oxybutynin IR)
Zero outcomes
Appendix 9.092: Dysgeusia (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.093: Dyspepsia (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.094: Dysphagia (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.095: Dysphonia (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.096: Epistaxis (Other Antimuscarinics versus Oxybutynin IR)
Zero Outcomes
Appendix 9.097: Fatigue (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.098: Gastrointestinal (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.099: Headache (Other Antimuscarinics versus Oxybutynin IR)
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Appendix 9.100: Nasopharyngitis (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.101: Nausea (Other Antimuscarinics versus Oxybutynin IR)
Zero Outcomes
Appendix 9.102: Somnolence (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.103: Treatment-related Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
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Appendix 9.104: Urinary Tract Infections (Other Antimuscarinics versus Oxybutynin IR)
Appendix 9.105: Balance Disorder (Other Antimuscarinics versus Tolterodine IR)
Zero Outcomes
Appendix 9.106: Blurred Vision (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.107: Confusional State (Other Antimuscarinics versus Tolterodine IR)
Zero Outcomes
Appendix 9.108: Constipation (Other Antimuscarinics versus Tolterodine IR)
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Appendix 9.109: Dizziness (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.110: Dry Mouth (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.111: Dyspepsia (Other Antimuscarinics versus Tolterodine IR)
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Appendix 9.112: Headache (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.113: Insomnia (Other Antimuscarinics versus Tolterodine IR)
Zero Outcomes
Appendix 9.114: Nausea (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.115: Nervousness (Other Antimuscarinics versus Tolterodine IR)
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Appendix 9.116: Somnolence (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.117: Urinary Retention (Other Antimuscarinics versus Tolterodine IR)
Appendix 9.118: Vomiting (Other Antimuscarinics versus Tolterodine IR)
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Appendix 9.119: Adverse Events (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.120: Constipation (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.121: Diarrhea (Other Antimuscarinics versus Tolterodine ER)
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Appendix 9.122: Dry Mouth (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.123: Headache (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.124: Influenza (Other Antimuscarinics versus Tolterodine ER)
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Appendix 9.125: Serious Adverse Events (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.126: Urinary Retention (Other Antimuscarinics versus Tolterodine ER)
Appendix 9.127: Administrative Problems – Treatment Discontinuation (Antimuscarinics 
versus Placebo)
Vouri et al. Page 74





















Appendix 9.128: Adverse Events – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
Appendix 9.129: Cognitive Function Adverse Events – Treatment Discontinuation 
(Antimuscarinics versus Placebo)
Appendix 9.130: Constipation – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
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Appendix 9.131: Death – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.132: Decline in Medical Condition – Treatment Discontinuation 
(Antimuscarinics versus Placebo)
Appendix 9.133: Did Not Meet Entrance Criteria – Treatment Discontinuation 
(Antimuscarinics versus Placebo)
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Appendix 9.134: Dizziness – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.135: Dry Mouth – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.136: Dry Throat – Treatment Discontinuation (Antimuscarinics versus Placebo)
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Appendix 9.137: Fall – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.138: Flatulence – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.139: Headache – Treatment Discontinuation (Antimuscarinics versus Placebo)
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Appendix 9.140: Heartburn/Gastroesophageal Reflux Disorder – Treatment Discontinuation 
(Antimuscarinics versus Placebo)
Appendix 9.141: Lost to Follow-up – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
Appendix 9.142: Other – Treatment Discontinuation (Antimuscarinics versus Placebo)
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Appendix 9.143: Protocol Violation – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
Appendix 9.144: Renal Pain – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.145: Serious Adverse Events – Treatment Discontinuation (Antimuscarinics 
versus Placebo)
Vouri et al. Page 80





















Appendix 9.146: Subject Non-Compliance – Treatment Discontinuation (Antimuscarinics 
versus Placebo)
Appendix 9.147: Total Discontinuation – Treatment Discontinuation (Antimuscarinics 
versus Placebo)
Appendix 9.148: Unsatisfactory Therapeutic Effect – Treatment Discontinuation 
(Antimuscarinics versus Placebo)
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Appendix 9.149: Urinary Retention – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
Appendix 9.150: Vertigo – Treatment Discontinuation (Antimuscarinics versus Placebo)
Appendix 9.151: Vision Blurred – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
Zero Outcomes
Appendix 9.152: Withdrew Consent – Treatment Discontinuation (Antimuscarinics versus 
Placebo)
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Appendix 9.153: Adverse Events – Treatment Discontinuation (Other Antimuscarinics 
versus Oxybutynin IR)
Appendix 9.154: Dry Mouth – Treatment Discontinuation (Other Antimuscarinics versus 
Oxybutynin IR)
Appendix 9.155: Total Discontinuation – Treatment Discontinuation (Other Antimuscarinics 
versus Oxybutynin IR)
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Appendix 9.156: Adverse Events – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine IR)
Appendix 9.157: Lost to Follow-up – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine IR)
Appendix 9.158: Personal Reasons – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine IR)
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Appendix 9.159: Protocol Violation – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine IR)
Appendix 9.160: Unsatisfactory Therapeutic effect – Treatment Discontinuation (Other 
Antimuscarinics versus Tolterodine IR)
Appendix 9.161: Withdrew Consent – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine IR)
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Appendix 9.162: Adverse Events – Treatment Discontinuation (Other Antimuscarinics 
versus Tolterodine ER)
Appendix 9.163: Constipation – Treatment Discontinuation (Other Antimuscarinics versus 
Tolterodine ER)
Appendix 9.164: Dry Mouth – Treatment Discontinuation (Other Antimuscarinics versus 
Tolterodine ER)
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Appendix 9.165: Headache – Treatment Discontinuation (Other Antimuscarinics versus 
Tolterodine ER)
Appendix 9.166: Vision Blurred – Treatment Discontinuation (Other Antimuscarinics versus 
Tolterodine ER)
Zero Outcomes
Appendix 9.167: Gastrointestinal Combined Adverse Events (Antimuscarinic versus 
Placebo)
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Appendix 9.168: Ocular/Visual Combined Adverse Events (Antimuscarinic versus Placebo)
Appendix 9.169: Pain-related Combined Adverse Events (Antimuscarinic versus Placebo)
Appendix 9.170: Cardiac Combined Adverse Events (Antimuscarinic versus Placebo)
Appendix 9.171: Falls Combined Adverse Events (Antimuscarinic versus Placebo)
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Appendix 9.172: Respiratory Tract-related Combined Adverse Events (Antimuscarinic 
versus Placebo)
Appendix 9.173: Neurological/Cognitive Combined Adverse Events (Antimuscarinic versus 
Placebo)
Appendix 9.174: Nasal Combined Adverse Events (Antimuscarinic versus Placebo)
Vouri et al. Page 89





















Appendix 9.175: Gastrointestinal Combined Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
Appendix 9.176: Ocular/Visual Combined Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
Appendix 9.177: Pain-related Combined Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
Zero Outcomes
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Appendix 9.178: Falls Combined Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
Appendix 9.179: Respiratory Tract-related Combined Adverse Events (Other 
Antimuscarinics versus Oxybutynin IR)
Appendix 9.180: Neurological/Cognitive Combined Adverse Events (Other Antimuscarinics 
versus Oxybutynin IR)
Appendix 9.181: Nasal Combined Adverse Events (Other Antimuscarinics versus 
Oxybutynin IR)
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Appendix 9.182: Gastrointestinal Combined Adverse Events (Other Antimuscarinics versus 
Tolterodine IR)
Appendix 9.183: Ocular/Visual Combined Adverse Events (Other Antimuscarinics versus 
Tolterodine IR)
Appendix 9.184: Falls Combined Adverse Events (Other Antimuscarinics versus Tolterodine 
IR)
Zero Outcomes
Appendix 9.185: Neurological/Cognitive Combined Adverse Events (Other Antimuscarinics 
versus Tolterodine IR)
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Appendix 9.186: Respiratory tract-related Combined Adverse Events (Other 
Antimuscarinics versus Tolterodine ER)
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• There are higher rates of anticholinergic AEs like dry mouth and constipation 
and treatment discontinuation in antimuscarinics versus placebo in the elderly
• There are higher rates of non-anticholinergic AEs, such as dyspepsia, 
dizziness, headache, and urinary tract infections in antimuscarinics versus 
placebo in the elderly
• In head-to-head trials, there are higher rates of AEs in fesoterodine compared 
to tolterodine extended-release in the elderly
• Due to the restrictive inclusion and exclusion criteria, these results should be 
further confirmed using pharmacoepidemiological techniques.
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